recombinant human erythropoietin
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04954989 | Oct → Dec 2024 overdue | — | Megalabs | Not yet recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03835507 | Jun 2016 → Dec 2020 | amyotrophic lateral sclerosis | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01783847 | Feb 2015 → Apr 2016 | optic nerve disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00910858 | Jan 2005 → Apr 2006 | myelodysplastic syndrome | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00808704 | Aug 2003 → Jul 2008 | brain hypoxia - ischemia | Zhengzhou University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00413946 | Jan 2006 → Dec 2012 | cerebral palsy, intracerebral hemorrhage, periventricular leukomalacia, specific developmental disorder | Swiss Neonatal Network | Completed | No outcome recorded |
| Phase 2 | NCT00121030 | Oct 2002 → Dec 2003 | anemia, female reproductive organ cancer | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00120679 | Oct 2002 → Dec 2003 | anemia, non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00120692 | Oct 2002 → Dec 2003 | anemia, breast cancer | Amgen | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05748561 | Apr 2022 → Apr 2024 | toxic optic neuropathy | Asociación para Evitar la Ceguera en México | Unknown | No outcome recorded |
| Phase 2/3 | NCT01624038 | Jun → Dec 2012 | beta-thalassemia intermedia | Ain Shams University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04910594 | Apr 2021 → Feb 2023 | anemia, lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT00144495 | Feb → Nov 2004 | chemotherapy-induced toxicity | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00144482 | Dec 2003 → Mar 2005 | chemotherapy-induced toxicity | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT01369732 | May 2011 → Jan 2013 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02036073 | Jan 2009 → Jun 2012 | — | Zhengzhou Children's Hospital, China | Completed | No outcome recorded |
| Phase 4 | NCT03317210 | Sep 2002 → Jul 2006 | anemia | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT00194857 | Feb 2002 → Dec 2005 | HIV infectious disease, anemia, chronic hepatitis C virus infection, neutropenia | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase not applicable5 trials · 1 met primary | ||||||
| — | NCT06968936 | Mar 2026 → Jun 2029 expected | iron deficiency anemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05353348 | Mar 2023 → Apr 2025 overdue | iron deficiency anemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05833477 | Oct → Dec 2022 | polycythemia | University of Copenhagen | Completed | No outcome recorded |
| — | NCT05053893 | Sep 2021 → Jul 2022 | cardio-renal syndrome | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| — | NCT02745990 | May 2016 → Dec 2022 | developmental disability | Huiqing Sun | Unknown | Met primary |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03786289 Comparator | Dec 2018 → Jul 2019 | — | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00910234 Comparator | Aug 2009 → Jul 2011 | intracerebral hemorrhage, periventricular leukomalacia, pulmonary immaturity, retinopathy of prematurity | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00313716 Comparator | Apr 2006 → Mar 2013 | anemia, traumatic brain injury | Claudia Sue Robertson | Completed | No outcome recorded |
| Phase 3 | NCT05669079 Background | Aug 2023 → Aug 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05907499 Background | Jul 2023 → Jul 2026 overdue | — | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05211167 Comparator | Jul 2021 → Jun 2023 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT03308448 Comparator | Jan 2018 → Aug 2022 | optic nerve disorder | Iran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT07162090 Comparator | Sep 2025 → Sep 2026 overdue | anemia due to chronic disorder, muscular atrophy | Tianjin Medical University General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04959578 Comparator | Feb 2018 → Jan 2019 | anemia due to chronic disorder | Rufaida Mazahir | Completed | Met primary |
| — | NCT01320449 Comparator | Aug 2011 → Jul 2012 | substance abuse | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human erythropoietin | “Before treatment initiation, subjects were randomized to subsequently receive growth factors, recombinant human erythropoietin (rHuEPO) and/or granulocyte colony-stimulating...” PMID 21876446 ↗ Nov 201133“Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously” NCT04954989 ↗ “Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT05211167 ↗ “Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.” NCT06796660 ↗ “Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week” NCT05053893 ↗ “Recombinant human erythropoietin injection (CHO cells)” NCT03786289 ↗ “recombinant human erythropoietin (rHuEPO)” PMID 23927461 ↗ Oct 2013 |
| Known as | Ebio | “domestic rHuEPO (trade name: Ebio).” NCT04910594 ↗ |
| Known as | Epiao | “Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.” NCT01624038 ↗ |
| Known as | EPO | “The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗2“The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24...” NCT00413946 ↗ “Recombinant human erythropoietin (EPO)” NCT07162090 ↗ |
| Known as | Human Erythropoiesis Injection (CHO cell) | “Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin” NCT05211167 ↗ |
| Known as | Recombinant erythropoietin injection (CHO cells) | “Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1” NCT03786289 ↗ |
| Known as | recombinant human Epo | “The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗ |
| Known as | rEpo | “High-dose recombinant human erythropoietin (rEpo) has first been administered in clinical trials for neuroprotection in very preterm neonates at high risk of brain injury and...” PMID 22776958 ↗ Jul 2012 |
| Known as | rhEPO | “The primary objective of this randomized, placebo-controlled study is to determine the effect of early administration of recombinant human Epo (rhEpo), on long-term...” NCT00313716 ↗2“The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients.” NCT03835507 ↗ “recombinant human erythropoietin (rhEpo)” NCT00910234 ↗ |
| Known as | rHuEPO | “Before treatment initiation, subjects were randomized to subsequently receive growth factors, recombinant human erythropoietin (rHuEPO) and/or granulocyte colony-stimulating...” PMID 21876446 ↗ Nov 20116“An open-label, randomized, non-inferiority study of darbepoetin alpha (DA) and recombinant human erythropoietin(rHuEpo) for the treatment of anemia in children with chronic...” NCT04959578 ↗ “ECAS survey showed that recombinant human erythropoietin (rHuEPO) was the main treatment for cancer anemia, but the treatment rate was low (17.4%)” NCT04910594 ↗ “patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy” NCT00120679 ↗ “with recombinant human erythropoietin (rhu-EPO) in myelodysplastic syndrome (MDS).” PMID 22936658 ↗ Aug 2012 “recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.” NCT00121030 ↗ “recombinant human erythropoietin (rHuEPO)” PMID 23927461 ↗ Oct 2013 |
| Known as | SEBOR | “Recombinant human erythropoietin (SEBOR, 10000 units / Branch) was injected subcutaneously once a week” NCT05053893 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human erythropoietin” NCT00144482 ↗ |
| Route | Subcutaneous | “s.c./week” NCT00144482 ↗ |